ArticleAntimicrobial agents and chemotherapy2020
Olorofim Susceptibility Testing of 1,423 Danish Mold Isolates Obtained in 2018-2019 Confirms Uniform and Broad-Spectrum Activity.
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Fusarium species,Scedosporium species, and Lomentospora prolificans: A systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- Elevated in vitro activity of ibrexafungerp against azole-resistant Candida isolates from Vulvovaginal Candidiasis (VVC): a multicentric study from India.Archives of microbiology · 2026Article
- Comment on: Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus.The Journal of antimicrobial chemotherapy · 2026Article
- Assessment of the molecular identification algorithm and its impact on antifungal susceptibilities against clinicalJAC-antimicrobial resistance · 2026Article
- Genomic Insights ofOpen forum infectious diseases · 2026Review
- Case Commentary: Successful use of olorofim for the treatment of multi-drug-resistantAntimicrobial agents and chemotherapy · 2025Article
- Olorofim activity against multidrug-resistantAntimicrobial agents and chemotherapy · 2025Article
- Successful use of olorofim for the treatment ofAntimicrobial agents and chemotherapy · 2025Article
- In vitro evaluation of olorofim and antifungal combinations against Aspergillus and Candida species.The Journal of antimicrobial chemotherapy · 2025Article
- Invasive Trichoderma longibrachiatum breakthrough infection in a hematology patient.Medical mycology case reports · 2025Article
- EUCAST olorofim MICs for 3,550 Danish mold and dermatophyte isolates from 2020 to 2023.Antimicrobial agents and chemotherapy · 2025Article
- Article
- Clinical significance and antifungal susceptibility profile of 103 clinical isolates ofJournal of clinical microbiology · 2025Article
- Trends of Azole-Resistant Aspergillus Fumigatus Susceptibility Over 12 Years from a German ECMM Excellence Center.Mycopathologia · 2025Article
- Review
- Refractory versus resistant invasive aspergillosis.The Journal of antimicrobial chemotherapy · 2025Review
- Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.Clinical microbiology reviews · 2024Review
- Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections.Clinical microbiology reviews · 2024Review
- The Role of Olorofim in the Treatment of Filamentous Fungal Infections: A Review of In Vitro and In Vivo Studies.Journal of fungi (Basel, Switzerland) · 2024Review
- Aspergillus fumigatus strains that evolve resistance to the agrochemical fungicide ipflufenoquin in vitro are also resistant to olorofim.Nature microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Olorofim is a novel antifungal drug in phase 2 trials. It has shown promising
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.